DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.
Lue lisääOsavuosikatsaus Q2'26
Osavuosikatsaus Q3'26
Vuosikatsaus '26
Liikevaihto t.
EBIT-% (oik.)
EPS (oik.)
Osinko %
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.